Table 7.

Demographic and clinical characteristics for the different genotypes of rs4353135 in UC patients

	rs4353135 TT	rs4353135 GT	rs4353135 GG	p value (Fisher or Kruskal–Wallis)
Gender
Male (n = 369)  Female (n = 321)	169 (53.3%) 148 (46.7%)	165 (55.2%) 134 (44.8%)	35 (47.5%) 39 (52.7%)	0.474
Age at diagnosis [years]
Median, q25–q75,  Min–max	27.4, 19.7–38.4, 3.2–79.6	28.7, 20.4–38.4, 2.9–78.1	29.3, 19.2–42.6, 3.9–72.1	0.628
Disease duration [years]
Median, q25–q75,  Min–max	10.9, 6.9–18.4, 0.3–49.5	11.5, 6.9–17.6, 0.2–48.7	13.1, 6.9–22.5, 1.0–45.3	0.580
Complications*
No (n = 286)  Yes (n = 404)	135 (42.6%) 182 (57.4%)	125 (41.8%) 174 (58.2%)	26 (35.1%) 48 (64.9%)	0.507
MTWAI**—maximal value throughout follow-up
Median, q25–q75,  Min–max	4, 2–9, 0–19	5, 2–9, 0–18	4, 2–7, 0–14	0.129
Reported flare*
No (n = 284)  Yes (n = 406)	121 (38.2%) 196 (61.8%)	130 (43.5%) 169 (56.5%)	33 (44.6%) 41 (55.4%)	0.329
Flare possibly or highly related to (focus on yes):
NSAIDs  Antibiotics  GI tract infection  Other infection  Treatment decr./disc  Other medication	11 (5.6%) 4 (2.0%) 32 (16.3%) 23 (11.7%) 50 (25.5%) 4 (2.0%)	11 (6.5%) 4 (2.4%) 34 (20.1%) 11 (6.5%) 41 (24.3%) 9 (5.3%)	1 (2.4%) 0 (0%) 8 (19.5%) 5 (12.2%) 7 (17.1%) 1 (2.4%)	0.705 1.000 0.632 0.168 0.543 0.219
Flare management (focus on the yes):
Hospitalization  Ambulatory  Surgery  Drug therapy	24 (12.2%) 67 (34.2%) 8 (4.1%) 178 (90.8%)	20 (11.8%) 30 (17.8%) 10 (5.9%) 150 (88.8%)	2 (4.9%) 7 (17.1%) 1 (2.4%) 40 (97.6%)	0.443 0.001 0.692 0.248
Focus on the hospitalizations:
Total days of hosp.  Median, q25–q75,  Min–max	6.5, 2.5–18.5, 0–90	0, 0–7, 0–41	3, 0–6, 0–6	0.038

Bold indicates a significant p-value (p < 0.05)